Nu-Med Plus (NUMD) Income from Continuing Operations (2012 - 2026)
Nu-Med Plus' (NUMD) quarterly Income from Continuing Operations came in at $19670.0 in Q2 2026, up 268.62% year-over-year from $5336.1 in Q2 2025, and up 255.89% quarter-over-quarter from -$12618.0 in Q4 2025.
Powered by 
Analysis
Nu-Med Plus (NUMD) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Nu-Med Plus has disclosed Income from Continuing Operations across 15 years of filings, most recently posting $19670.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 268.62% year-over-year to $19670.0; the TTM figure through Jun 2026 stood at -$16579.0 (up 72.75% YoY), while the FY2025 annual figure was -$56182.0, up 17.8% from the prior year.
- Income from Continuing Operations came in at $19670.0 for Q2 2026 at Nu-Med Plus, up from -$12618.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of $42606.0 in Q4 2022 to a low of -$59653.0 in Q1 2022.
- Average Income from Continuing Operations over 5 years is -$21385.3, with a median of -$18677.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations slumped 232.84% in 2023 and jumped 268.62% in 2026.
- Over 5 years, Income from Continuing Operations stood at $42606.0 in 2022, then tumbled by 232.84% to -$56596.0 in 2023, then soared by 81.35% to -$10555.0 in 2024, then fell by 19.55% to -$12618.0 in 2025, then surged by 255.89% to $19670.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were $19670.0 in Q2 2026, -$12618.0 in Q4 2025, and -$11966.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 19,670.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19,670.00 |
| Dec 31, 2025 | -12,618.00 |
| Sep 30, 2025 | -11,966.00 |
| Jun 30, 2025 | -11,665.00 |
| Mar 31, 2025 | -19,933.00 |
| Dec 31, 2024 | -10,555.00 |
| Sep 30, 2024 | -18,677.00 |
| Jun 30, 2024 | -17,287.00 |
| Mar 31, 2024 | -21,826.00 |
| Dec 31, 2023 | -56,596.00 |
| Sep 30, 2023 | -16,406.00 |
| Jun 30, 2023 | -24,320.00 |
| Mar 31, 2023 | -28,204.00 |
| Dec 31, 2022 | 42,606.00 |
| Sep 30, 2022 | -58,050.00 |
| Jun 30, 2022 | -58,070.00 |
| Mar 31, 2022 | -59,653.00 |
| Dec 31, 2021 | -112,341.00 |
| Sep 30, 2021 | -118,366.00 |
| Jun 30, 2021 | -242,606.00 |